evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,257 questions · 1,337 findings · 183 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 175 · 13.1%GRADE not reported 212 · 15.9%Very low 286 · 21.4%Low 341 · 25.5%Moderate 254 · 19%High 69 · 5.2%

Intervention not reported

Process evaluation (user satisfaction) Measures: Self‐designed Likert scale, VAS scale · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Caregivers‐related outcomes · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in short‐term disability 3 months or less after the start of the intervention Measures: GLTEQ · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in long‐term disability more than 3 months after the intervention Measure:6MWT · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in impairments directly post‐intervention Measures: FIS, FSS, MFIS, MS Symptom Cheklist · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in short‐term impairments 3 months or less after the start of the intervention Measures: FIS · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in long‐term impairments more than 3 months after the intervention Measures: FIS, FSS · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in participation · People with multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Change in psychological outcomes Measures:CES‐D, HADS, SDMT · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in quality of life Measures: QWB, HAQUAMS, MSIS‐29, SF‐36, LMSQOLS, · People with multiple sclerosis
1 finding from 1 review

Plerixafor vs placebo

Mortality (12 months) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor showed no clear difference in mortality (12 months) compared with placebo (moderate certainty).

1 finding from 1 review

Plerixafor vs placebo

Successful stem cell collection · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor leads to higher successful stem cell collection compared with placebo (high certainty).

1 finding from 1 review

Plerixafor vs placebo

Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).

1 finding from 1 review

Intervention not reported

The proportion of patients with at least one relapse at two years · Patients with relapsing‐remitting multiple sclerosis

The intervention probably leads to lower the proportion of patients with at least one relapse at two years (moderate certainty).

1 finding from 1 review

Intervention not reported

The proportion of patients with disability worsening at two years · Patients with relapsing‐remitting multiple sclerosis

The intervention may leads to lower the proportion of patients with disability worsening at two years (low certainty).

1 finding from 1 review